Sai Parenteral's Share Price Today

Sai Parenterals to host investor meet in Hyderabad on Oct 14

Sai Parenterals Ltd will hold an investor meeting on October 14, 2026. The event starts at 11:00 am at the company's Hyderabad facilities. Discussions will be limited to publicly available information only. No unpublished price sensitive information (UPSI) will be disclosed.

Sai Parenterals appoints new CS and COO after officer resignation

Sai Parenterals Limited accepted Shivali Aggarwal's resignation as CS & Compliance Officer effective September 30, 2026. Ashwani Singh Bisht appointed as new Company Secretary and Compliance Officer with 12+ years of experience. Arvind Gannimitta named Chief Operating Officer, bringing 26+ years of pharmaceutical operations expertise. Board meeting held at Hyderabad registered office approved all personnel changes simultaneously.

Sai Parenterals shareholders approve all 12 AGM resolutions despite ESOP dissent

All 12 resolutions passed at Sai Parenterals' 25th AGM on September 10, 2026. Board reappointments for Anil Kumar Karusala and Vijitha Gorrepati approved. Institutional investors voted 26.3% against the ESOP Scheme 2025 ratification. Related-party loan to Sai Singapore for Noumed Pharmaceuticals funding approved. IPO proceeds utilisation timeline extended for capacity expansion and R&D.

Sai Parenteral wins Rs 204 crore order from Australia pharmacy chain

Sai Parenteral secured a Rs 204 crore OTC medicines supply agreement with an Australian pharmacy chain. The 3-year contract covers manufacturing, regulatory compliance, and nationwide distribution. Total disclosed order book stands at Rs 5613 crore across 7 orders in the last 3 quarters. Order book coverage is 41.78 quarters of average quarterly revenue. Consolidated revenue grew 132.7% YoY to Rs 381.00 crore in FY26.

Sai Parenterals hosts analyst meet on August 31 in Mumbai

Sai Parenterals hosts analyst/institutional investor meet on August 31, 2026. Physical group meeting scheduled in Mumbai at 10:00 am. Strategic Growth Advisors Pvt. Ltd. hosting the event. Discussions limited to publicly available information only.

Sai Parenterals redirects ₹1,018.57 crore IPO funds for M&A

Sai Parenterals Limited proposes to utilise ₹1,018.57 million of unutilised IPO proceeds to acquire 60% stakes in Saicriti Pharma and Prathyak Laboratories. This strategic shift replaces organic expansion plans due to regulatory constraints under the Hyderabad Industrial Lands Transformation Policy. The move aims to secure immediate manufacturing capacity and R&D capabilities while navigating urban relocation mandates.